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repair; A4, 14 patients who had single ventricle and were treated with Fontan type opera- 
tion. Group B was subdivided into 3 groups; B1, 6 patients with C-CHD palliated by clas- 
sic Glenn procedure; B2, 6 patients with C-CHD palliated by shunt procedure; B3, 9 
healthy controls. There was no significant difference in age among subgroups of A and 
among subgroups of B. Blood samples were obtained from upper arm veins and serum 
VEGF was determined by ELISA method. We determined correlation between patient's 
arterial saturation and serum VEGF in combined group of A1, A2, B1, B2 and B3 and 
compared level of serum VEGF among groups. Data were expressed as median and 
inter-quartile range in parenthesis. RESULTS: Serum VEGF was significantly negatively 
correlated with arterial saturation (r=.48, p<.001). Serum VEGF in A1 was significantly 
higher than those in A2 and A3 [373(269) pg/ml in A1 vs. 196(121) pg/ml in A2 and 
186(87) pg/ml in A3, respectively[, but not higher than VEGF in A4 [257(293) pg,'ml]. 
Although it did not reach significant level, serum VEGF in A4 tended to be higher than A3 
(p=.07). Serum VEGF in B1 and B2 was significantly higher than in B3 [269(379) pg/ml in 
B1 and 657(382) pg/ml in B2 vs. 225(105) pg/ml in B3, respectively]. There was no signif- 
icant difference in serum VEGF level between B1 and B2. CONCLUSIONS: Patients with 
C-CHD seem to have increased serum VEGF in parallel with the degree of cyanosis. 
Patients with C-CHD palliated by classic Glenn procedure do have increased serum 
VEGF, but not more than those palliated by shunt procedure. With bi-ventricular repair, 
cyanosis disappears and serum VEGF may be normalized. In contrast, with Fontan type 
operation, cyanosis disappears but serum VEGF may not be normalized 
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Kawaseki Disease and the Gamma Globulin Therapy 
Inhibit Leukocyte-Endothel ial  Cell Adhesion 
Rvuii Fukazawa. Yohoko Uchikoba, Yukio Kuramochi, Ei Iksgami, Mitsuhire Kamisago, 
Yasuhiro Katsube, Takashi Seki, Shunichi Ogawa, Nippon Medical School, Tokyo, Japan. 
(Background) We have revealed massive expression of Ca binding protein migration 
inhibitory factor-related protein(MRP) on circulating granulocyte in acute phase of 
Kawesaki disease. Newton et. aL (J Immunol 1998 160:1427) reported MRP reinforce 
the ability of adhesion molecule Mac-l, which suggest the relationship between MRP/ 
Mac-1 and vasculitis. We quantified leukocytes Mac-1 expression in Kewaseki disease, 
and evaluated the adhesion ability between cultured human coronary artery endothelial 
cell and Kawasaki disease patient's peripheral eukocyte. Furthermore, we evaluate the 
leukocyte-endothelial cell adhesive ability using the patients' plasma, before and after 
gamma globulin therapy, to see the gamma globulin effect for this system. (Materials 
and Methods) mRNA was extracted from the Kawasaki disease patients' leukocyte 
(n=21) and was converted to cDNA by RT-PCR, and Mac-1 expression was evaluated by 
quantitative PCR (Applied Biosystems; GeneAmp 5700). Patients' leukocyte, labeled 
with BCECF-AM, exposed to cultured human coronary artery endothelial cell, and leuko- 
cyte adhesion assay was performed. Leukocyte adhesion assay was also carded out 
using the patients' plasma, pre/post gamma globulin therapy. (Result) Mac-I expression 
was a peak on acute phase of Kawasaki disease and significantly decreased after 1 
month of onset. The patients' leukocyte adhesion ability to endothelial cell was signifi- 
cantly increased, which was significantly inhibited by addition of anti-Mac-1 antibody. And 
the patients' plasma before gamma globulin therapy significantly increased leukocyte- 
endothelial cell adhesion, which was abolished by the plasma of post gamma globulin 
therapy. We postulated Mac-1 play the key rote for leukocyte invasion into endothelium, 
which is the initial step for causing vasculitis. And the gamma globulin therapy is effective 
through inhibiting leukocyte-endothelial cell adhesion. 
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1142-97 Termination of Intraatrial Reentrant Tachycardia Using 
Implanted Pacemakers in Patients Following Atrial 
Switch Repair of  Transposition of the Great Arteries 
Gerald A. Sarwer. David J. Bradley, Peter S. Fischbach, Kristen A. George, Sarah S. 
Leroy, Macdonald Dick, II, University of Michigan Congenital Heart Center, Ann Arbor, 
Michigan. 
Background: Intra-atriat reentrant echycardia (IART) has been associated with patients 
(pts) following the atrial switch operation (AtrS) for d-transposition of the great arteries 
who have sick sinus syndrome (SSS). Anti-tachycardic pacing (ATP) has been used to 
convert IART in these pts but its efficacy using implanted pacemakers and safety have 
been questioned. 
Methods: Clinical records of pts post AtrS who had undergone atrial or dual chamber 
pacemaker placement for SSS were retrospoctively reviewed. Implant details, number 
and results of ATP attempts, medications, and outcomes were recorded. 
Results: Of the 29 pts identified, atrial electrode placement was endocardial in 25 and 
epicardial in 4 and was guided only by pacing threshold data with no attempt o induce 
and convert IART at implant. 21 (72%) had 1 or more episodes of IART and all were tak- 
ing digoxin, 5 on beta-blockers, and 2 on amiodarone. 4 of 21 had IART prior to pace- 
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maker implant without recurrence post implant. 17 underwent ATP for conversion of I to 
30 episodes per patient (94 total episodes, median 3/patient). 7 pts experiencing 47 epi- 
sodes had automatic anti-tachycardic pacemakers. ATP therapy consisted of 15 to 40 
beats at a cycle length of 50% to 80% of the IART cycle length (median 67%, minimum 
150 ms) delivered at an amplitude and pulse width twice the bradycardia pacing settings. 
ATP cycle length began at 80% of the IART cycle length and was decreased until conver- 
sion. All episodes were converted but many required multiple attempts. 8 ATP attempts 
increased the IART rate but not the ventricular ate. 4 ATP attempts in 2 pts caused atrial 
fibrillation that reverted spontaneously to sinus rhythm. All pts were hemodynamically 
stable in IART before and during ATP. 
Conclusion: Bradycardia pacing can control IART in some pts. ATP by implanted pace- 
makers is safe and effective in converting IART in pts post AtrS procedure who are not 
severely hemodynamically compromised by IART avoiding the need for DC cardiover- 
sion. IART induction is not required at pacemaker implant. Pacemakers with atrial over- 
drive capability should be considered in pts post AtrS with SSS as the incidence of IART 
is high and ATP is highly effective and safe. 
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Resistant Accessory Pathways in Children 
David J. Bradlev. Loren M. Madden, Christopher B. Stefanelli, Elizabeth V. Saarel, 
Jeremy D. Ashes, Gerald A, Serwer, Peter S. Fischbach, Macdonald Dick, II, University 
of Michigan Congenital Heart Center, Ann Arbor, Michigan. 
Background: Adenosine (Adn) is routinely used during electrophysiolgic study (EPS) of 
patients with supravantricular tachycardia (SVT) to assess presence of accessory atrio- 
ventricular pathways lAP) and verify success of radiofrequency ablation (RFA). Adenos- 
ine blocks conduction in the atrioventricu)ar node, but generally not in APe. We 
investigated the incidence and properties of Adn-sensitive APs. 
Methods: The electrophysiologic patient database at the University of Michigan Congen- 
ital Heart Center was queried for all patients with accessory pathways and SVT undergo- 
ing EPS between 4-1995 and 4-2001. Clinical records and EPS tracings were reviewed. 
Patients received Adn during ventricular pacing at a standard intravenous close of 
200mcg/kg, with a maximum dose of 12mg was used. All patients were under 21 years of 
age (median 11.6 years). 
Results: A total of 151 patients with APe and SVT were identified; Adn was used in 132 
patients (137 APe). Of these, 20 APs (15%) blocked with adenosine. RFA was performed 
on 85% (117/137) APe, and was successful in 94% (15/16) Adn-sensitive, v 92% (93/ 
101 ) Adn-insensitive APe (p=ns). Adn-sensitive and -insensitive APe did not differ signifi- 
cantly with regard to patient age (10.6±5.8 v 11.4±4.7 years), gender (47% v 55% boys), 
or SVT cycle length (314±39 v 315±46ms), procedure times, total RF applications or rate 
of ablation success. Adn-sensitive and insensitive pathways did not segregate by septal 
v free-wall (35% v 28% septal, p--0.16), or left v right sided (63% v 60% left, p=0.36) loca- 
tions. In contrast, Ado-sensitive APe were less likely to demonstrate pre-excitation in 
sinus rhythm (37% v 61%, p=0.04), and had significantly longer antegrade effective 
refractory periods (ERP) when pre-excitation was present (340-Z42 v278+58ms; p=0.05). 
Retrograde ERP also trended longer in Adn-sensitive pathways (270~57 v 259±43) 
though this difference was not statistically significant (p=0.10). 
Conclualona: As Adn-sensitive APs occur frequently in pediatric patients, Adn is not an 
absolute test of AP presence. Adn-sensitive APs are significantly less likely than Adn- 
resistant APs to cause pre-excitation, and have longer entegrade ERPs when they do. 
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Background: The HELEX TM device has recently been used in humans for transcathater 
secundum atrial septal defect (ASD) closure. We report the data on the biologic response 
to implantation of this device in the canine heart. Methods: Histologic data from 23 ani- 
mals enrolled in non-randomized prospective studies conducted at W.L. Gore & Associ- 
ates Inc and The Cleveland Clinic Foundation were analyzed. Animals had either a 
surgically created or a percutaneously created ASD and immediate implantation of a 
HELEX TM device, Animals were sacrificed at intervals from 2 days to 1 year. Devices 
were examined grossly, with multiple sections of the device and adjacent atrial septum 
assessed for fibrous connective tissue (FCT) and endothelial-like cell coverage. Distal 
organs were examined for the presence of thrombo-emboli in animals with implanted 
devices _> 30 days, Results: FCT completely covered the left atrial component in 12/13 
devices, which had been implanted _> 30 days. One device at 6 months post implantation 
had complete coverage of the right atrial side with extensive coverage of the left atrial 
side. Endothelial-like cell coverage was muitifocal or greater in 10/13 devices implanted 
-> 30 days. One device examined by scanning electron microscopy and immunohis- 
tochemistry (for factor VIII) confirmed that the endothelial-like cells seen with bight 
microscopy were true endothelial cells. There was a trend for greater FCT and endothe- 
lial cell coverage of devices with time. There was no evidence of distal organ throm- 
boembolism in any animal examined. Conclusions: The biologic response to 
implantation of the HELEX TM device appears to be progressive with an initial fibrous con- 
nective tissue coverage followed by endothetialization. There was complete coverage of 
the left atrial side of the device with fibrous connective tissue by 30 clays post implanta- 
tion in almost all cases with no evidence of distal thromboembolism. These data support 
the notion that the HELEX TM device is biocompatible. Further research into the process of 
endothelialization of this and other transcatheter devices is needed. 
